<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2271">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334512</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-044</org_study_id>
    <nct_id>NCT04334512</nct_id>
  </id_info>
  <brief_title>A Study of Quintuple Therapy to Treat COVID-19 Infection</brief_title>
  <acronym>HAZDpaC</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSCS CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II interventional study will test the efficacy of quintuple therapy
      (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of
      patients with COVID-19 infection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study patients will be treated with a combination therapy to determine if this
      combination can effectively treat COVID-19. Treatment will last ten days. The study will last
      24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Randomized, Double-Blind, Placebo-Controlled Phase II interventional Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of days from COVID-19 diagnosis to recovery via RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction or Progression of Symptomatic Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction and/or progression of symptomatic days, reduction of symptom severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of Quintuple Therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the symptom response to study therapy as measured by the survey in the EDC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of Quintuple Therapy via pulse</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pulse from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of Quintuple Therapy via oxygen saturation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Oxygen saturation from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of Quintuple Therapy via EKG</measure>
    <time_frame>12 weeks</time_frame>
    <description>EKG response from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Tolerability of Quintuple Therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess Adverse Events and Serious Adverse Events due to Quintuple Therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Coronavirus-19</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with quintuple therapy for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Treatment with hydroxychloroquine</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Treatment with azithromycin</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Treatment with vitamin C</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Treatment with vitamin D</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Treatment with Zinc</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Informed consent provided electronically via the EDC, demonstrating that the subject
             understands the procedures required for the study and the purpose of the study

          2. Male or female subjects 18 years of age and up

          3. Subjects must agree to practice at least two highly effective methods of birth control
             for the duration of the study. This includes condoms with spermicide, oral birth
             control pills, contraceptive implants, intra-uterine devices, or diaphragms. At least
             one of these must be a barrier method. Subjects not of reproductive potential will be
             exempt (e.g. post-menopausal, surgically sterilized)

          4. Diagnosis of COVID-19 by RT-PCR

        Exclusion Criteria

          1. Refusal to provide informed consent

          2. Diarrhea prior to infection

          3. Any comorbidities which, in the opinion of the investigator, constitute health risk
             for the subject

          4. Any contraindications for treatment with hydroxychloroquine

               1. Hypoglycemia

               2. Known G6PD deficiency

               3. Porphyria

               4. Anemia

               5. Neutropenia

               6. Alcoholism

               7. Myasthenia gravis

               8. Skeletal muscle disorders

               9. Maculopathy

              10. Changes in visual field

              11. Liver disease

              12. Psoriasis

          5. Anemia from pyruvate kinase and G6PD deficiencies

          6. Abnormal EKG with QT prolongation acquired or from birth

          7. Allergies to 4-Aminoquinolines

          8. History of jaundice or high fevers prior to developing COVID-19

          9. Treatment with any of the medications listed in Appendix II

         10. Treatment with any other drug not listed that affects the QT interval

         11. Treatment with any anti-epileptic drug, whether prescribed for seizures or otherwise.

         12. Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-339-0549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>217-494-6692</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Banjanac M, Munić Kos V, Nujić K, Vrančić M, Belamarić D, Crnković S, Hlevnjak M, Eraković Haber V. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3.</citation>
    <PMID>22766077</PMID>
  </reference>
  <reference>
    <citation>Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.</citation>
    <PMID>32173110</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.</citation>
    <PMID>32052466</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

